Related Experiment Video

Updated: Jul 20, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

Regression of left ventricular hypertrophy during antihypertensive treatment

Bertin Foading Deffo1

  • 1Department of Cardiology, Clinique Saint-Jean, Brussels, Belgium. foadingbertin@hotmail.com

Acta Cardiologica
|September 15, 2006
PubMed

Insights

Left ventricular hypertrophy regression during antihypertensive treatment lowers cardiovascular risk. This case study shows significant regression in a Black patient, highlighting treatment benefits for this high-risk population.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Clinical Case Studies

Background:

  • Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular events and stroke.
  • Essential arterial hypertension disproportionately affects Black populations, leading to end-organ damage like LVH.
  • Regression of LVH during antihypertensive treatment is linked to reduced cardiovascular mortality and improved prognosis.

Observation:

  • This report details a case of significant regression of left ventricular hypertrophy.
  • The regression was observed in a sub-Saharan African patient undergoing antihypertensive treatment.
  • Evaluation methods included 12-lead electrocardiography and echocardiography.

Findings:

  • Significant regression of left ventricular hypertrophy was achieved.
  • The patient was a sub-Saharan African individual with essential arterial hypertension.
  • Antihypertensive treatment was the primary intervention.

Implications:

  • Demonstrates the potential for substantial LVH regression in Black patients with hypertension.
  • Highlights the importance of effective antihypertensive strategies in high-risk populations.
  • Suggests that regression of LVH can improve cardiovascular outcomes in diverse patient groups.

More Related Videos

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...